Pfizer touts Australian results
An Australian study sponsored by Abrysvo maker Pfizer has reinforced the effectiveness of maternal immunisation to help protect infants from serious respiratory syncytial virus (RSV) disease during their most vulnerable months.
To see the whole article, log in or create an account.